The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The role of bone marrow stromal cells in myeloma progression and drug resistance
Olga Blau, MD, Charité Campus Virchow Clinic, Berlin, Germany, explores the impact of bone marrow stromal cells on multiple myeloma progression and drug resistance. Her study highlights differences in gene expression in stromal cells from patients with active versus inactive myeloma and throughout disease progression. Adding lenalidomide and elotuzumab to stromal co-cultures significantly altered gene expression, with daratumumab having a lesser effect. This underscores the role of stromal cell interactions in myeloma progression and drug resistance. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
